Ursofalk - hepatoprotective agent.  Tablets Ursofalk

Pharmacological action Ursofalk

Ursofalk of instruction has choleretic, damaging cholesterol stones, cholesterol-lowering effect.

The drug protects the cell membranes of the liver and biliary tract from damage by toxic bile acids and prevents the growth of connective tissue in the liver in the case of damage to hepatocytes.

Ursofalk contains in its composition ursodeoxycholic acid. It is as if the structural shell separates the smallest structures of bile acids - a so-called mixed micelles. Ursodeoxycholic acid also interacts with lipophilic membrane structure, making them resistant to damage. So she realizes cytoprotective (protective) action.

Decreasing the amount of cholesterol in the bile is realized by reducing its reabsorption in the intestine, suppression of the formation in the liver and reduce excretion into the bile. The bile content increases bile acids, thereby dissolve cholesterol gallstones, and new ones are not formed.

Like its analogs Ursofalk enhances the secretion of gastric and pancreatic cancer.

The drug has immunological effects - influence on the content of different classes of immune cells in the body, and at the level of the liver - slows down the development of fibrosis in patients with cystic fibrosis, primary biliary cirrhosis, alcoholic liver disease, reduces the risk of esophageal varices. There are positive reviews Ursofalk when incorporated into treatment of malignant diseases of the colon (cancer), it is able to inhibit the growth of tumor cells.

Product form

Ursofalk release capsules of 250 mg and a suspension (250 ml flasks, the contents of ursodeoxycholic acid - 250 mg / 5 mL).

Indications Ursofalk

The drug is prescribed for the treatment of primary biliary cirrhosis, subject to the compensated state, biliary reflux gastritis, for the dissolution of cholesterol gallstones in the case of cholestasis during parenteral nutrition in the complex treatment of cystic fibrosis, biliary dyskinesia. He recommended to prevent the development of colon cancer in high-risk groups for the disease.

No age restrictions. Thus, the use Ursofalk as a means of reducing the level of indirect bilirubin in the blood, possibly in neonates conjugation hyperbilirubinemia (jaundice).


Ursofalk according to the instructions do not use it at individual intolerance, in the case of gallstones rentgenpolozhitelnyh (they contain a lot of calcium), inflammatory diseases of the biliary tract and intestines, decompensated cirrhosis of the liver, gallbladder non-operation, in violation of the kidney, liver or pancreas.

Instructions for use Ursofalk

1 The drug is taken once a day (overnight) inside. The capsule is swallowed without opening the envelope, washed down with water. The average daily dose ursofalk calculated on the weight of the patient's body and is 10 mg / kg / day. If the dosage exceeds the average, the daily dose can be divided into 2 - 3 doses. The suspension Ursofalk recommended for the treatment of children under 3 years of age and patients weighing less than 34 kg, as well as difficulty swallowing. The drug is recommended to take a long time - from several months to 2 years without treatment interruptions.

To dissolve gallstones before starting treatment, make sure that they are cholesterol (in the X-ray can not see them), no larger than 20 mm, the gall bladder is filled no more than half, while maintaining patency of the biliary tract. Like its counterparts Ursofalk not recommend the use of the means at the same time, increases the content of cholesterol in the bile (clofibrate, estrogens, and others.). Antacids impair the absorption of the drug.  The suspension Ursofalk

In the event of dissolution of gallstone disease duration stones from 6 to 24 months, but if after 12 months from the initiation of the positive dynamics is not observed, it is possible to cancel Ursofalk as they further treatment is inappropriate. To monitor the effectiveness of treatment should be twice a year to explore the liver and bile duct by ultrasound and X-ray.

When biliary reflux gastritis and reflux esophagitis course of taking an average lasts 10 - 14 days.

In cystic fibrosis Ursofalk daily dose of up to 20 - 30 mg / kg / day, in primary biliary cirrhosis and 15 - 20 mg / kg / day.

Analogues are Ursofalk Ursosan, Urdoksa and Ursodez.

Side effects

In the opinion of Ursofalk sometimes cause allergic reactions, diarrhea, dyspepsia, calcination gallstones.